{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:06:52Z","timestamp":1789578412230,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.7759\/cureus.112017","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:30:13Z","timestamp":1783132213000},"source":"Crossref","is-referenced-by-count":1,"title":["Adipokine Profile in Non-alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Trisha","family":"C","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat Kumar","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Ch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Chinnapaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachakra Kushal","family":"Thota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek J","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al.. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023, 8:20-30. 10.1016\/S2468-1253(22)00317-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"5","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021, 5:2212-24. 10.1016\/S0140-6736(20)32511-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne CD","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020, 72:785-801. 10.1016\/j.jhep.2020.01.013","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg H","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology. 2021, 73:833-42. 10.1002\/hep.31518","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-22. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biology11081237","article-title":"Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?","volume":"11","author":"Francisco V","year":"2022","unstructured":"Francisco V, Sanz MJ, Real JT, Marques P, Capuozzo M, Ait Eldjoudi D, Gualillo O. Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?. Biology. 2022, 11:1237. 10.3390\/biology11081237","journal-title":"Biology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.1.33","article-title":"Association of adipokines with development and progression of nonalcoholic fatty liver disease","volume":"33","author":"Boutari C","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab. 2018, 33:33-43. 10.3803\/EnM.2018.33.1.33","journal-title":"Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.11.006","article-title":"Adipokines in nonalcoholic fatty liver disease","volume":"65","author":"Polyzos SA","year":"2016","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016, 65:1062-79. 10.1016\/j.metabol.2015.11.006","journal-title":"Metabolism"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154028","article-title":"Adiponectin and leptin in the diagnosis and therapy of NAFLD","volume":"103","author":"Boutari C","year":"2020","unstructured":"Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism. 2020, 103:154028. 10.1016\/j.metabol.2019.154028","journal-title":"Metabolism"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos SA","year":"2011","unstructured":"Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011, 60:313-26. 10.1016\/j.metabol.2010.09.003","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12333","article-title":"Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review","volume":"17","author":"Bekaert M","year":"2016","unstructured":"Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016, 17:68-80. 10.1111\/obr.12333","journal-title":"Obes Rev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3769-3","article-title":"Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"59","author":"Polyzos SA","year":"2016","unstructured":"Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016, 59:30-43. 10.1007\/s00125-015-3769-3","journal-title":"Diabetologia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.01.002","article-title":"Adipocytokines and hepatic fibrosis","volume":"26","author":"Saxena NK","year":"2015","unstructured":"Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab. 2015, 26:153-61. 10.1016\/j.tem.2015.01.002","journal-title":"Trends Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002630","article-title":"Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines","volume":"95","author":"Jamali R","year":"2016","unstructured":"Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine. 2016, 95:e2630. 10.1097\/MD.0000000000002630","journal-title":"Medicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-2-21","article-title":"Visfatin, glucose metabolism and vascular disease: a review of evidence","volume":"2","author":"Saddi-Rosa P","year":"2010","unstructured":"Saddi-Rosa P, Oliveira CS, Giuffrida FM, Reis AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010, 2:21. 10.1186\/1758-5996-2-21","journal-title":"Diabetol Metab Syndr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2015.02.006","article-title":"Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology","volume":"5","author":"Duseja A","year":"2015","unstructured":"Duseja A, Singh SP, Saraswat VA, et al.. Non-alcoholic fatty liver disease and metabolic syndrome-position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015, 5:51-68. 10.1016\/j.jceh.2015.02.006","journal-title":"J Clin Exp Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507652-adipokine-profile-in-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:30:18Z","timestamp":1783132218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507652-adipokine-profile-in-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.112017","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}